Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.
| 3.72 | |
| 3.69 | |
| - | |
| 3.73 | |
| 3.69 | |
| 1-4.39 | |
| 588 M | |
| 153 M | |
| 10 000 K | |
| 0.887 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Ultragenyx Pharmaceutical Inc. RARE incurred a loss of $2.25 per share in second-quarter 2023, wider than the Zacks Consensus Estimate of a loss of $2.11. The company reported a loss of $2.26 per shar...
Ultragenyx Pharmaceutical Inc. RARE reported dosing the first group of patients in both its late-stage studies evaluating setrusumab (UX143) in young adults and pediatric patients with Osteogenesis Im...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
